Both AEHR and AMAT sit squarely within the semiconductor ecosystem that is being reshaped by demand for artificial intelligence (AI) computing, yet they occupy very different positions on that value chain. Aehr Test Systems supplies specialized test and burn-in systems, while Applied Materials supplies the broad capital equipment used to fabricate chips. This stock comparison is most relevant to investors weighing a high-beta, small-cap growth story against a diversified, large-cap leader. Because the two names differ sharply in size, valuation, momentum, and risk, examining their relative performance and market positioning can clarify which profile better suits the current environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
AEHR, or Aehr Test Systems, designs wafer-level and package-level test and burn-in systems used to improve the reliability of semiconductor devices, with growing exposure to AI processors, silicon photonics, and power devices. In recent weeks, the company delivered a standout quarter, swinging to a net profit as revenue roughly tripled year over year to about $33 million. Bookings exceeded revenue, and backlog climbed above $100 million, prompting management to raise its fiscal 2027 revenue outlook to around $150 million.
Despite strong fundamentals, the stock has been unusually volatile. It rallied sharply over one recent stretch, then gave back a large portion of those gains as investors reassessed valuation. The company also added former Meta AI infrastructure leader Vijay Rao to its board, underscoring its AI ambitions. Sentiment is split: analysts maintain Buy ratings with price targets well above current levels, but a P/S ratio in the low-30s and meaningful insider selling highlight the premium investors are being asked to pay for growth. From what I see, this volatility warrants close monitoring.
AMAT, or Applied Materials, is the largest U.S. manufacturer of semiconductor equipment, serving foundries, memory makers, and integrated device manufacturers (IDMs, or companies that both design and fabricate their own chips). Its portfolio spans deposition, etch, metrology, and advanced packaging, giving it broad exposure to the entire chipmaking process. In its most recent quarter, revenue rose about 53% year over year to a record $10.41 billion, while non-GAAP earnings per share (EPS) nearly doubled, driven by robust demand tied to AI and high-bandwidth memory (HBM, the stacked memory used in advanced AI processors).
Unlike its smaller peer, AMAT combines accelerating growth with consistent profitability, a modest dividend, and a large-scale share buyback program. Still, the stock has not been immune to the broader semiconductor sell-off: shares pulled back meaningfully from mid-year highs amid concerns over interest rates and the durability of AI capital spending. With a forward P/E near 20x and a market capitalization near $280 billion, it offers a fundamentally different risk profile than AEHR. One thing that stands out here is the sustained margin expansion.
The clearest contrast between these two names is scale and diversification. AMAT generates tens of billions in annual revenue across a broad, established customer base, while AEHR is a roughly $1.7 billion company whose growth still leans heavily on a concentrated set of AI and data-center customers. This concentration is both AEHR's biggest catalyst and its largest risk: a single customer pause could materially reset expectations.
On momentum, AEHR has shown far more dramatic swings, reflecting its higher beta and thinner float, whereas AMAT has moved more in line with the broader semiconductor sector. Valuation also diverges sharply: AEHR trades near 32x sales with no meaningful trailing earnings base, while AMAT trades near 20x forward earnings with a record of profitability. Finally, AMAT returns cash through dividends and buybacks, a dimension where AEHR offers little by comparison.
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor AMAT in the current environment. AEHR offers a higher-octane growth trajectory, but its elevated valuation, customer concentration, and recent volatility introduce greater uncertainty in the near term. AMAT, by contrast, pairs record results and sustained margin expansion with a more diversified revenue base and a more balanced valuation. While no outcome is certain, the combination of steadier trends and broader market positioning gives AMAT a probabilistically stronger profile for the risk-conscious comparison.
In my research process, I frequently turn to Tickeron’s AI Trading Bots to run scenario tests on names like these and compare automated strategies against current market conditions. It helps me quickly evaluate how different approaches might perform across varying volatility levels without relying solely on manual charting.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 50-day moving average for AEHR moved below the 200-day moving average on November 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEHR as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for AEHR entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AEHR's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for AEHR just turned positive on November 03, 2026. Looking at past instances where AEHR's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Following a +21.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEHR advanced for three days, in 243 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.970) is normal, around the industry mean (5.670). AEHR has a moderately low P/E Ratio (-232.913) as compared to the industry average of (68.795). Projected Growth (PEG Ratio) (0.927) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (27.897).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AEHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of burn-in and test equipment for semiconductor manufacturing
Industry ElectronicProductionEquipment